CoChat

Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks

Barf, Tjeerd, Kaptein, Allard · 2012 · Journal of Medicinal Chemistry

The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.

Abstract

ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTIrreversible Protein Kinase Inhibitors: Balancing the Benefits and RisksTjeerd Barf* and Allard KapteinView Author Information Drug Discovery Unit, Covalution Pharma BV, Ravenstein, The Netherlands*Phone: +31 618 193139. E-mail, [email protected]Cite this: J. Med. Chem. 2012, 55, 14, 6243–6262Publication Date (Web):May 23, 2012Publication History Received7 March 2012Published online8 June 2012Published inissue 26 July 2012https://pubs.acs.org/doi/10.1021/jm3003203https://doi.org/10.1021/jm3003203review-articleACS PublicationsCopyright © 2012 American Chemical SocietyRequest reuse permissionsArticle Views13870Altmetric-Citations266LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Inhibition,Inhibitors,Kinase inhibitors,Monomers,Peptides and proteins Get e-Alerts

Overview

Integrity signals

Registry

Crossref · 10.1021/jm3003203

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 108 references

Research works printed but not linked: 5

  1. Powis G., 1994, Cancer Res., 54, 2419
  2. Wood E. R., 2008, Proc. Natl. Acad. Sci. U.S.A., 105, 2772
  3. Brigdes A. J., 2000, Chem. Rev., 101, 2541
  4. Advani, R.; Sharman, J.; Smith, S.; Boyd, T.; Grant, B.; Kolibaba, K.; Furman, R.; Buggy, J.; Loury, D.; Hedrick, E.; Izumi, R.; Hamdy, A.; Fowler, N.The Btk Inhibitor PCI-32765 Is Highly Active and Well Tolerated in Patients with Relapsed/Refractory B Cell Malignancies: Final Results from a Phase I Study. Presented at the 11th International Conference on Malignant Lymphoma (ICML), Lugano, Switzerland, June 15–18, 2011.
  5. Petter, R.Targeted Covalent Kinase Inhibitors: AVL 292 as a Potent, Irreversible and Selective Inhibitor of Btk. Presented at the 5th Anglo-Swedish Medicinal Chemistry Symposium (ASMC), Åre, Sweden, March 20–23, 2011.

Cited by

See all 386

Metadata

Authors
Barf, T., & Kaptein, A.
Affiliations
Drug Discovery Unit, Covalution Pharma BV, Ravenstein, The Netherlands
Corresponding author
Barf, Tjeerd
Venue
Journal of Medicinal Chemistry
Published
2012-06-08
Volume
55
Issue
14
Pages
6243-6262
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2057079741
Cited by
331
References
108
Citations by year
2026: 14 · 2025: 16 · 2024: 21 · 2023: 17 · 2022: 9 · 2021: 30 · 2020: 38 · 2019: 26 · 2018: 22 · 2017: 38 · 2016: 32 · 2015: 22 · 2014: 25 · 2013: 14 · 2012: 7
FWCI
2.10
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
kinase inhibitors, covalent inhibitors, drug development, benefits and risks, kinase-targeted therapy
MeSH terms
Animals, Cell Line, Humans, Protein Kinases, Risk, Structure-Activity Relationship, Time Factors, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks. https://app.cochat.ai/papers/10.1021/jm3003203
The paper
Barf, T., & Kaptein, A. (2012). Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks. Journal of Medicinal Chemistry. https://doi.org/10.1021/jm3003203

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.